Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Tuesday, 17'th Feb 2026
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allspring Emerging Growth Fund Q4 2025 Performance Review
02:24pm, Wednesday, 04'th Feb 2026
Allspring Emerging Growth Fund Q4 2025 Performance Review
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)
10:36am, Monday, 26'th Jan 2026
Tarsus Pharmaceuticals (TARS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst
SG Americas Securities LLC Sells 27,833 Shares of Tarsus Pharmaceuticals, Inc. $TARS
05:14am, Monday, 26'th Jan 2026
SG Americas Securities LLC lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 81.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institu
BMRN or TARS: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 13'th Jan 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more
Bobak Azamian Sells 6,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock
05:24am, Thursday, 01'st Jan 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) CEO Bobak Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The shares
Envestnet Asset Management Inc. Buys 1,418 Shares of Tarsus Pharmaceuticals, Inc. $TARS
03:58am, Thursday, 27'th Nov 2025
Envestnet Asset Management Inc. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 15.9% during the undefined quarter, according to the company in its most recent filin
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3
01:46pm, Thursday, 20'th Nov 2025
Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex bl
Campbell & CO Investment Adviser LLC Invests $416,000 in Tarsus Pharmaceuticals, Inc. $TARS
04:37am, Monday, 17'th Nov 2025
Campbell and CO Investment Adviser LLC acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) in the undefined quarter, according to the company in its most recent disclosure with the
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript
10:56pm, Tuesday, 04'th Nov 2025
Tarsus Pharmaceuticals, Inc. ( TARS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants David Nakasone - Head of Investor Relations Bobak Azamian - Co-Founder, President, CEO & C
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates
06:56pm, Tuesday, 04'th Nov 2025
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.61 per share a year ago.
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
04:05pm, Tuesday, 04'th Nov 2025
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
05:00pm, Tuesday, 28'th Oct 2025
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
07:46am, Monday, 06'th Oct 2025
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off
01:05pm, Friday, 26'th Sep 2025
TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive str
